{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:49:39Z","timestamp":1717573779282},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Malignancy-induced hypercalcemia is a very rare condition in children whereas it is more common among adult patients with malignancy. The mechanisms of malignancy-induced hypercalcemia include the over-secretion of parathyroid hormone-related protein (PTHrP), osteolytic metastases and the over-production of 1,25-dihydroxyvitamin D (calcitriol). Although hypercalcemia due to PTHrP secretion has been published before, overproduction of calcitriol has not been reported yet in pediatric squamous cell skin carcinoma cases. Herein, we report calcitriol-mediated severe hypercalcemia in a 5-year-old boy with squamous cell skin carcinoma arising in the background of xeroderma pigmentosum (XP) which responded well to zoledronate treatment. To the best of our knowledge, this is the first pediatric case of malignancy-induced hypercalcemia which is mediated by calcitriol in squamous cell skin carcinoma.<\/jats:p>","DOI":"10.1515\/jpem-2019-0158","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T09:02:58Z","timestamp":1575018178000},"page":"1403-1406","source":"Crossref","is-referenced-by-count":3,"title":["Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum"],"prefix":"10.1515","volume":"32","author":[{"given":"Ulkem","family":"Colak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul Y.","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu O.","family":"Sozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra B.","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulya","family":"Kayserili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukru","family":"Hatun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MOP.0b013e32833b7c23","article-title":"Hypercalcemia in children and adolescents","volume":"22","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.14740\/wjon907w","article-title":"Denosumab Therapy for refractory hypercalcemia secondary to squamous cell carcinoma of skin in Epidermolysis Bullosa","volume":"6","year":"2015","journal-title":"World J Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/tp.2017.09.10","article-title":"Zoledronic acid in pediatric metabolic bone disorders","volume":"6","year":"2017","journal-title":"Transl Pediatr"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MOP.0b013e32833b7c23","article-title":"Hypercalcemia in children and adolescents","volume":"22","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"ref331","first-page":"329","article-title":"Humoral hypercalcemia of malignancy in squamous cell carcinoma of the skin: parathyroid hormone\u2013related protein as a cause","volume":"94","year":"2001","journal-title":"South Med J"},{"key":"ref161","first-page":"329","article-title":"Humoral hypercalcemia of malignancy in squamous cell carcinoma of the skin: parathyroid hormone\u2013related protein as a cause","volume":"94","year":"2001","journal-title":"South Med J"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fped.2017.00233","article-title":"Malignancy-induced hypercalcemia \u2013 diagnostic challenges","volume":"5","year":"2017","journal-title":"Front Pediatr"},{"key":"ref101","first-page":"709","article-title":"The use of pamidronate for acute vitamin D intoxication, clinical experience with three cases","volume":"28","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1210\/jc.2013-2016","article-title":"Calcitriol-mediated hypercalcemia: causes and course in 101 patients","volume":"98","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/jid.2011.426","article-title":"Shining a light on Xeroderma Pigmentosum","volume":"132","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dnarep.2011.03.005","article-title":"A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients","volume":"10","year":"2011","journal-title":"DNA Repair"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1346-8138.1996.tb04055.x","article-title":"Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma","volume":"23","year":"1996","journal-title":"J Dermatol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.1617","article-title":"Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine","volume":"27","year":"2012","journal-title":"J Bone Miner Res"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V82.5.1383.1383","article-title":"Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphomas","volume":"82","year":"1993","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1001\/jama.289.24.3300","article-title":"Sarcoidosis","volume":"289","year":"2003","journal-title":"J Am Med Assoc"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fped.2017.00233","article-title":"Malignancy-induced hypercalcemia \u2013 diagnostic challenges","volume":"5","year":"2017","journal-title":"Front Pediatr"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/tp.2017.09.10","article-title":"Zoledronic acid in pediatric metabolic bone disorders","volume":"6","year":"2017","journal-title":"Transl Pediatr"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1001\/jama.289.24.3300","article-title":"Sarcoidosis","volume":"289","year":"2003","journal-title":"J Am Med Assoc"},{"key":"ref61","first-page":"1159","article-title":"Xeroderma pigmentosum-facts and perspectives","volume":"38","year":"2018","journal-title":"Anticancer Res"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1210\/jc.2013-2016","article-title":"Calcitriol-mediated hypercalcemia: causes and course in 101 patients","volume":"98","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.1617","article-title":"Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine","volume":"27","year":"2012","journal-title":"J Bone Miner Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dnarep.2011.03.005","article-title":"A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients","volume":"10","year":"2011","journal-title":"DNA Repair"},{"key":"ref271","first-page":"709","article-title":"The use of pamidronate for acute vitamin D intoxication, clinical experience with three cases","volume":"28","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","year":"2015","journal-title":"N Am J Med Sci"},{"key":"ref81","first-page":"495","article-title":"Vitamin D endocrine system and osteoclasts","volume":"3","year":"2014","journal-title":"Bonekey Rep"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V82.5.1383.1383","article-title":"Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphomas","volume":"82","year":"1993","journal-title":"Blood"},{"key":"ref251","first-page":"495","article-title":"Vitamin D endocrine system and osteoclasts","volume":"3","year":"2014","journal-title":"Bonekey Rep"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"345","DOI":"10.14740\/wjon907w","article-title":"Denosumab Therapy for refractory hypercalcemia secondary to squamous cell carcinoma of skin in Epidermolysis Bullosa","volume":"6","year":"2015","journal-title":"World J Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/jid.2011.426","article-title":"Shining a light on Xeroderma Pigmentosum","volume":"132","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref231","first-page":"1159","article-title":"Xeroderma pigmentosum-facts and perspectives","volume":"38","year":"2018","journal-title":"Anticancer Res"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","year":"2015","journal-title":"N Am J Med Sci"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1346-8138.1996.tb04055.x","article-title":"Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma","volume":"23","year":"1996","journal-title":"J Dermatol"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2019.32.issue-12\/jpem-2019-0158\/jpem-2019-0158.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:45:57Z","timestamp":1619055957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0158\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":34,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1515\/jpem-2019-0158","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,18]]}}}